Until you can grasp the magnitude of our opportunity, you should probably bow out of these discussions.
RAC commenced preclinical work with Zan + immunotherapies in 2021 and are yet to report on the outcomes. If these were to prove fruitless, the anthracycline synergy opportunity is already enormous. But, I suspect the reason we've heard zip is due to the IP protection strategy.
Industry news, page-2124
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.66 | $1.61 | $117.0K | 71.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12252 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 900 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |